Radiopharm Theranostics Ltd (RADX) Receivables (2023 - 2026)

Radiopharm Theranostics (RADX) has reported Receivables for 4 consecutive years, with $123763.9 the latest figure, recorded in Q2 2026.

• On a quarterly basis, Receivables rose 85.82% year-over-year to $123763.9 in Q2 2026; TTM through Jun 2026 was $123763.9, a 85.82% increase from a year earlier, with the FY2026 full-year figure at $118495.9, down 98.86% from the prior year.
• Receivables was $123763.9 for Q2 2026 at Radiopharm Theranostics, up from $66605.4 in the prior quarter.
• Over five years, Receivables peaked at $6.3 million in Q4 2024 and troughed at $6507.3 in Q2 2024.
• A 4-year average of $2.2 million and a median of $123763.9 in 2026 frame the typical range for Receivables.
• Across the five-year window, Receivables slumped 99.85% in 2024 and jumped 923.55% in 2025, its largest moves.
• Over 4 years, Receivables stood at $4.5 million in 2023, then surged by 39.9% to $6.3 million in 2024, then slumped by 98.93% to $66605.4 in 2025, then surged by 85.82% to $123763.9 in 2026.
• The last three Receivables figures came in at $123763.9 (Q2 2026), $66605.4 (Q2 2025), and $6.3 million (Q4 2024), per Business Quant data.